Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at...
InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at...
View ArticleEnrollment commences in InterMune's Esbriet Phase 3 study for IPF
InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.
View ArticleInterMune to launch Esbriet for German patients with IPF
InterMune, Inc. today announced that Esbriet will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available in Europe since it...
View ArticleInterMune reports new data from Esbriet clinical trial on IPF
InterMune, Inc. today reported that new data was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet(pirfenidone) in...
View ArticleIQWiG publishes report on Esbriet benefit assessment for treatment of IPF
InterMune, Inc. today reported that the private Institute for Quality and Efficiency in Health Care (IQWiG) has today published its report on the benefit assessment of Esbriet (pirfenidone) for the...
View ArticleIQWiG examines added benefit of pirfenidone for idiopathic pulmonary fibrosis
Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since...
View ArticleInterMune reaches definitive agreement with Vidara to sell Actimmune
InterMune, Inc. today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in a cash...
View ArticleNew analyses from Esbriet RECAP study in IPF patients presented at ERS 2012
InterMune, Inc. announced that new analyses of data from the RECAP extension study of Esbriet (pirfenidone) were presented today at the 2012 Annual Congress of the European Respiratory Society (ERS) in...
View ArticleInterMune receives Health Canada approval for Esbriet to treat idiopathic...
InterMune, Inc. today announced that Health Canada has approved Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in adult patients.
View ArticleAIFA approves pricing and reimbursement conditions for InterMune's Esbriet
InterMune, Inc. today announced that the Board of the Italian Drug Agency has approved the pricing and reimbursement conditions for Esbriet (pirfenidone), and that the agreement has been published in...
View ArticleIPF World Week underlines the need for integrated approach towards idiopathic...
This year's IPF World Week (September 21-29) sees healthcare professionals, patient advocacy groups, people living with idiopathic pulmonary fibrosis (IPF), who have an estimated median survival time...
View ArticleGenoa Pharmaceuticals, McMaster University report additional benefits of...
Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of...
View ArticlePFF Patient Communication Center: The destination for latest disease...
The newly launched Pulmonary Fibrosis Foundation Patient Communication Center (PCC) has become the destination for the most up-to-date information for the pulmonary fibrosis community. The PCC now has...
View ArticleFirst Edition: May 19, 2014
Today's headlines include a report about federal health care subsidies and an update on states small business health exchanges.
View ArticleResearchers identify drugs to slow progression of idiopathic pulmonary fibrosis
Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently...
View ArticleFDA grants orphan-drug designation to Genoa's pirfenidone for treatment of...
Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Genoa for the use of...
View ArticleViewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to...
You're looking at the biggest story involving the federal budget and a crucial one for the future of the American economy. Every year for the last six years in a row, the Congressional Budget Office...
View Article2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet...
This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only...
View ArticleAIFA approves pricing and reimbursement conditions for InterMune's Esbriet
InterMune, Inc. today announced that the Board of the Italian Drug Agency has approved the pricing and reimbursement conditions for Esbriet (pirfenidone), and that the agreement has been published in...
View ArticleIPF World Week underlines the need for integrated approach towards idiopathic...
This year's IPF World Week (September 21-29) sees healthcare professionals, patient advocacy groups, people living with idiopathic pulmonary fibrosis (IPF), who have an estimated median survival time...
View Article